User Tools

Site Tools

Trace: • pain
office_hours:pain:start

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
office_hours:pain:start [2026/02/14 17:03] – [Pain Management Series] andrew2393cnsoffice_hours:pain:start [2026/02/15 03:28] (current) – andrew2393cns
Line 1: Line 1:
-====== Pain Management Series ====== +{{ :office_hours:series:pain.png?400 |}}
- +
 ===== Overview ===== ===== Overview =====
  
Line 133: Line 131:
 ===== V. Pharmacologic Drug Classes ===== ===== V. Pharmacologic Drug Classes =====
  
-Pain pharmacotherapy must match mechanism.+Pain pharmacotherapy must match mechanism. This series will cover the drugs that can be used for pain
  
-This series will cover the following drug classes: +See: [[pain_management:drug_classes|Pain Pharmacotherapy]]
- +
----- +
- +
-==== Anti-Inflammatory Agents ==== +
- +
-  * [[cardio:anti_inflammatory:nsaids|NSAIDs]] +
-  * [[endocrine:corticosteroids|Corticosteroids]] +
-  * [[pain_management:acetaminophen|Acetaminophen]] +
- +
-Mechanism: +
-  Decrease prostaglandin-mediated sensitization. +
- +
----- +
- +
-==== Voltage-Gated Sodium Channel Antagonists ==== +
- +
-  * [[neuro:local_anesthetics|Lidocaine]] +
-  * Suzetrigine (Nav 1.8 selective antagonist) +
- +
-Mechanism: +
-  Block action potential propagation in nociceptors. +
- +
----- +
- +
-==== Gabapentinoids ==== +
- +
-  * [[neuro:anticonvulsants|Gabapentin]] +
-  * [[neuro:anticonvulsants|Pregabalin]] +
- +
-Mechanism: +
-  Bind α2δ calcium channel subunit → decrease glutamate & substance P release. +
- +
----- +
- +
-==== Serotonin & Norepinephrine Reuptake Inhibitors ==== +
- +
-  * [[psychiatry:snri|SNRIs]] +
-  * [[psychiatry:tca|Tricyclic Antidepressants (TCAs)]] +
- +
-Mechanism: +
-  Enhance descending inhibitory pathways. +
- +
----- +
- +
-==== NMDA Receptor Antagonists ==== +
- +
-  * [[neuro:nmda_antagonists|Ketamine]] +
- +
-Mechanism: +
-  Reduce central sensitization and wind-up. +
- +
----- +
- +
-==== Opioid Analgesics ==== +
- +
-  * [[controlled_substances:opioids|Opioids]] +
- +
-Mechanism: +
-  μ-receptor activation → decrease ascending pain transmission. +
- +
----- +
- +
-==== NK1 Receptor Antagonists (Investigational for Pain) ==== +
- +
-  * [[gi:antiemetics:nk1_antagonists|NK1 Antagonists]] +
- +
-Mechanism: +
-  Block Substance P at NK1 receptors. +
- +
-Clinical role in chronic pain remains limited. +
- +
----- +
- +
-==== Nerve Growth Factor (NGF) Antibodies ==== +
- +
-  * Tanezumab +
-  * Fasinumab +
- +
-Mechanism: +
-  Block NGF-mediated nociceptor sensitization. +
- +
-Not currently approved due to safety concerns. +
- +
----- +
- +
-==== Cannabinoids ==== +
- +
-  * THC +
-  * CBD +
- +
-Mechanism: +
-  CB1/CB2 receptor modulation (evidence evolving).+
  
 ---- ----
Line 264: Line 170:
   * • Multimodal therapy reduces risk     * • Multimodal therapy reduces risk  
 </WRAP> </WRAP>
 +
 +----
 +
 +
office_hours/pain/start.1771088629.txt.gz · Last modified: by andrew2393cns